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Abstract
Background
There are no effective treatments or validated clinical response markers in systemic sclero-
sis (SSc). We assessed imaging biomarkers and performed gene expression profiling in a
single-arm open-label clinical trial of tyrosine kinase inhibitor dasatinib in patients with SSc-
associated interstitial lung disease (SSc-ILD).
Methods
Primary objectives were safety and pharmacokinetics. Secondary outcomes included clini-
cal assessments, quantitative high-resolution computed tomography (HRCT) of the chest,
serum biomarker assays and skin biopsy-based gene expression subset assignments. Clini-
cal response was defined as decrease of >5 or >20% from baseline in the modified Rodnan
Skin Score (MRSS). Pulmonary function was assessed at baseline and day 169.
Results
Dasatinib was well-tolerated in 31 patients receiving drug for a median of nine months. No
significant changes in clinical assessments or serum biomarkers were seen at six months.
By quantitative HRCT, 65% of patients showed no progression of lung fibrosis, and 39%
showed no progression of total ILD. Among 12 subjects with available baseline and post-
treatment skin biopsies, three were improvers and nine were non-improvers. Improvers
mapped to the fibroproliferative or normal-like subsets, while seven out of nine non-improv-
ers were in the inflammatory subset (p = 0.0455). Improvers showed stability in forced vital
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capacity (FVC) and diffusing capacity for carbon monoxide (DLCO), while both measures
showed a decline in non-improvers (p = 0.1289 and p = 0.0195, respectively). Inflammatory
gene expression subset was associated with higher baseline HRCT score (p = 0.0556).
Non-improvers showed significant increase in lung fibrosis (p = 0.0313).
Conclusions
In patients with SSc-ILD dasatinib treatment was associated with acceptable safety profile
but no significant clinical efficacy. Patients in the inflammatory gene expression subset
showed increase in skin fibrosis, decreasing pulmonary function and worsening lung fibrosis
during the study. These findings suggest that target tissue-specific gene expression analy-
ses can help match patients and therapeutic interventions in heterogeneous diseases such
as SSc, and quantitative HRCT is useful for assessing clinical outcomes.
Trial registration
Clinicaltrials.gov NCT00764309
Introduction
Systemic sclerosis (SSc) is a clinically heterogeneous orphan disease characterized by autoim-
munity, widespread microangiopathy and multi-organ fibrosis [1,2]. Progressive fibrosis in
the skin and lungs accounts for the significant morbidity and mortality of SSc [3]. In the skin,
excessive matrix deposition causes stiffening and tightening, as assessed by the modified Rod-
nan Skin Score (MRSS), while in the lungs, fibrosis causes respiratory insufficiency associated
with restrictive physiologic changes and interstitial lung disease (ILD) detected by high resolu-
tion computed tomography (HRCT) [4,5]. Despite significant recent advances toward eluci-
dating the pathogenesis and uncovering novel targets, effective disease-modifying therapy for
SSc remains elusive [6].
The profibrotic cytokines transforming growth factor beta (TGF-β) and platelet-derived
growth factor (PDGF) are established as key pathogenic mediators of skin and lung fibrosis in
SSc [7,8]. Tyrosine kinases are implicated in profibrotic intracellular signaling cascades down-
stream of both TGF-β and PDGF receptors, and therefore represent potential therapeutic tar-
gets in SSc [9–11]. Significant challenges remain in the development of effective therapies for
SSc [6]. These include marked patient-to-patient heterogeneity in clinical features and molecu-
lar drivers of disease, variable trajectories for the rate of disease progression in different organs
even for the same individual, unpredictable clinical outcomes and the lack of robust prognostic
and diagnostic biomarkers. Transcriptome analysis of target organs such as skin and lungs,
and quantitative assessment of the extent of radiological lung involvement on HRCT represent
promising novel strategies in this regard [12]. In particular, HRCT has been shown to be pre-
dictive of survival in SSc, and changes in texture-based quantitative measures are potential sur-
rogate biomarkers of treatment response in clinical trials [13].
The broad-spectrum tyrosine kinase inhibitor (TKI) dasatinib was originally developed to
target breakpoint cluster region-Abelson tyrosine-protein kinase 1 (BCR-Abl) and is now
widely used in the treatment of chronic myeloid leukemia (CML) [14–17]. The potent inhibi-
tory effects of dasatinib on c-Abl, PDGF receptor and Src kinase activities suggest that it may
have anti-fibrotic efficacy [18,19]. Indeed, in preclinical models dasatinib was shown to
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mitigate bleomycin-induced dermal fibrosis [18] and reduce lung inflammation and silica-
induced pulmonary fibrosis [20] in mice. Furthermore, dasatinib inhibits T-cell receptor sig-
naling and the production of inflammatory and fibrotic cytokines [21–23]. These consider-
ations prompted us to undertake an open-label clinical trial to evaluate the safety of dasatinib
in SSc patients with associated ILD. As secondary and exploratory outcomes, we evaluated the
utility of radiologic texture-based quantitative imaging biomarkers, combined with skin-based
gene expression profiling, in predicting and monitoring treatment response.
Materials and methods
Study protocol
We undertook a multicenter, single-arm, open-label Phase 2a trial (NCT00764309) of dasati-
nib (Bristol-Myers Squibb, Princeton, NJ) in SSc-ILD. Patients received dasatinib (100 mg)
once daily for 6 months (primary endpoint), and were followed for up to 18 additional months
to assess longer-term safety. The protocol was approved by the Institutional Review Boards/
Independent Ethics Committees from each participating center: Western Institutional Review
Board, Olympia, WA, USA; University of Michigan IRBMED, Ann Arbor, MI, USA; Lifespan
Institutional Review Board, Providence, RI, USA; Mayo Clinic Institutional Review Board,
Rochester, MN, USA and MUSC Institutional Review Board for Human Research, Charleston,
SC, USA. Written informed consent was received from each patient before study entry. Date
range for participant recruitment and follow-up was January 2009 through April 2011. CON-
SORT checklist is provided as S1 Checklist and complete study protocol is included in S1 File.
Eligible patients were18 years old with the diagnosis of diffuse cutaneous SSc (dcSSc),
according to the American College of Rheumatology criteria and the LeRoy classification
[24,25]. Inclusion criteria included disease duration (defined as the interval from first non-
Raynaud disease manifestation) 3 years, and MRSS15 [26]. Patients had to have func-
tional evidence of pulmonary involvement (defined as forced vital capacity (FVC) between
45% and 80% of predicted normal and/or diffusing capacity for carbon monoxide (DLCO)
between 30% and 70% of predicted normal) and/or HRCT evidence for ILD (defined as
ground glass opacities, inter-and intra-lobular septal thickening, traction bronchiectasis, and/
or honeycombing). Treatment with methotrexate, cyclophosphamide or D-penicillamine was
discontinued at least 12 weeks prior to enrollment, while steroids (at a dose<10 mg or equiva-
lent of prednisone/day) could be continued at a stable dose. The full list of inclusion and exclu-
sion criteria is shown in S1 Table.
Safety and pharmacokinetics
Physical examinations and assessment of vital signs and laboratory values were completed at
screening and at day 1, 15, 29, and monthly thereafter throughout the course of the study.
Blood samples were collected for pharmacokinetics (PK) analysis on day 15 pre-dose and 0.5,
1, 1.5, 2, 3, 4, 6 and 8 hours post-dose. Plasma samples were analyzed by liquid chromatogra-
phy tandem mass spectrometry and pharmacokinetic parameters were estimated using non-
compartmental analysis [27].
Efficacy assessments
Safety was the primary outcome. Efficacy outcomes included change at day 169 compared to
baseline in the following parameters: MRSS, pulmonary function test (PFT) results, the Mahler
Transitional Dyspnea Index (TDI), and HRCT of the lungs. HRCT scans were performed at
baseline and at 6-month follow-up. A standardized HRCT protocol was followed at all sites
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and a rigorous ongoing quality control program was used to ensure patient compliance with
breath-hold and acquisition guidelines [28]. A computer-aided diagnosis (CAD) system was
used to segment the lungs and quantitate the extent and changes in parenchymal abnormalities
[29,30]. This technique utilizes a texture feature classification that has been trained to allow
quantitation (Q) of four parameters of ILD: lung fibrosis (QLF), ground glass (QGG), honey-
comb cysts (QHC), and a combination of all three, quantitative interstitial lung disease
(QILD) [30,31]. Thresholds of 3% changes for the most severe lobe and 2% changes for the
whole lung were considered as meaningful changes [30]. In addition, all HRCT studies were
also scored visually using a modified Kazerooni scoring system [32] that utilizes a standardized
Likert scale (0 = absent; 1 = 1–5%; 2 = 6–25%; 3 = 26–50%; 4 = 51–75%; and 5 = 76–100%) for
each component (ground glass opacities, fibrosis and honeycomb cysts). Scoring was per-
formed by two blinded readers. Discordant reads were reviewed by a consensus reading; the
majority score was recorded. All HRCT scans were read with respect to each lung, and each
lobe. Comparison of baseline and 6-month HRCT scans was carried out by randomly assign-
ing one of the two scans as “scan A” and the other one as “scan B” and each component and
lobe was scored as better, same or worse by the two readers [33].
Serum markers
Serum levels of Krebs von den Lungen-6 (KL-6), surfactant protein D (SP-D), a B cell prolifer-
ation-inducing ligand (APRIL) and adiponectin were determined at baseline and serially dur-
ing the trial by enzyme-linked immunosorbent assay (ELISA) using kits from BioVendor or
from Millipore (EZHMWA-64K and EZHADP-61K).
Skin biopsies
Biopsies of skin on the dorsal forearms (10 cm distal to the olecranon) were performed at base-
line and on day 169. Repeat biopsies were performed within 1 cm of the initial biopsy site.
RNA isolation, labeling and hybridization
RNA was isolated from skin biopsies by RNeasy Fibrous Tissue Mini Kit (Qiagen), with on-
column DNase digestion. RNA quality was monitored by Agilent 2100 Bioanalyzer (Agilent
Technologies). RNA quantity was measured with NanoDrop (Thermo Fisher Scientific). RNA
samples were arrayed into 96-Well Microtiter Microplates (Thermo Fisher Scientific). 50 ng of
skin RNA for each sample was amplified and labeled with WT-Ovation Pico System and
Encore Biotin Module (NuGEN Technologies). 2.5 μg of labeled cDNA was hybridized on
GeneChip HT HG-U133A Array Plate (Affymetrix).
Chip quality check and expression data generation
Scanned images were visually inspected and chip quality report was generated by Expression
Console Software (Affymetrix). Image data were processed using Robust Multichip Average
(RMA) [34] to determine specific hybridizing signal for each gene. CEL files were pre-pro-
cessed via RMA generating a combined dataset with 45 samples and 22,277 probes. The gene
expression data have been uploaded to NCBI GEO (GSE79387).
Intrinsic gene expression subset assignment and pathway enrichment
analysis
Intrinsic genes were determined as previously described [35]. Differential gene expression and
pathway enrichment analyses were performed as recently described [36]. Briefly, differentially
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expressed genes were determined using GenePattern [37] module ComparativeMarkerSelec-
tion [38] and differentially expressed pathways were identified via Gene Set Enrichment Anal-
ysis [39,40] run vs. Hallmark database [41].
Statistical analysis
All patients who received1 dose of study drug were included in the safety analysis. Baseline
and change from baseline values for each study visit were summarized using descriptive statis-
tics for PFTs, TDI, and MRSS. The TDI scores represent either an improvement (positive) or
worsening (negative). Serum adiponectin levels at baseline and at the end of the study were
compared with the Wilcoxon signed-rank test. For HRCT fibrosis scoring, changes relative to
baseline for each lobe type and overall were summarized for subjects with at least one follow-
up paired scan (note that two patients had less than 6-month follow-up). Changes in quantita-
tive scores were classified as “not worse” (if >3 or >2% decrease from baseline score or stable
within ±3% or ±2% changes in most severe baseline lobe or whole lung, respectively), or worse
(if>3 or >2% increase from baseline score in most severe baseline lobe or whole lung, respec-
tively) [30,42]. Spearman rank correlations were used to test associations among radiological
data, PFT, MRSS, and serum markers. Kruskal-Wallis rank tests were used to compare the
continuous CAD or FVC scores by the categorical visual assessment.
Gene signature centroids were generated by averaging expression values of each gene across
all given samples (e.g. across all baseline improver samples). Categorical variables were ana-
lyzed via Fisher’s exact test. Mann-Whitney and Wilcoxon signed-rank tests were used to com-
pare PFT measures and HRCT quantitative scores between improver/non-improver and
baseline/post-treatment groups, respectively. Data were plotted as mean ± standard error of
the mean (SEM) scatter plots. Statistical analyses were performed in Stata (version 14.0) and
GraphPad Prism (Windows, version 6.05).
Results
Patient characteristics
Of 47 screened subjects, 31 (66%) received1 dose (100 mg) dasatinib. Baseline demographics
and disease characteristics are summarized in Table 1. The mean age was 50.8 years (range 24–
77), 67.7% were female, 77.4% were white, and median disease duration from first non-Ray-
naud disease manifestation was 14.1 months. At baseline, the mean MRSS was 24.5, FVC was
2.9 L, and DLCO was 14.2 mL/min/mmHg. Discontinuations from the study before day 169
(primary endpoint) occurred in eight patients, and were due to an adverse event (AE) (n = 5),
lack of efficacy (n = 2) or withdrawn consent (n = 1). Patient allocation is provided as CON-
SORT flowchart in Fig 1.
Pharmacokinetics summary
In 21 evaluable subjects, the geometric mean maximum concentration (Cmax) and area under
the curve (AUC) were 40.1 ng/mL (92% CV) and 119.0 ng•h/mL (73% CV), respectively. The
median tmax was 1.5 h (range: 0.5–4) and the mean t-half was 2.7 h ± 0.9.
Safety outcomes
Overall, dasatinib was well tolerated in this cohort of patients with early-stage SSc-ILD. No sig-
nificant cardiac toxicity was observed. Of a total of 31 reported AEs, diarrhea and nausea were
most common (S2 Table). A total of 7 serious AEs were recorded (S3 Table).
Novel CT biomarkers and genomic subsetting of SSc-ILD
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Clinical efficacy outcomes
The change (mean ± standard deviation) in MRSS from baseline to day 169 was –1.8 ± 9.9
(p = 0.1531; n = 21). At follow-up, the change to day 365 was –7.6 ± 4.7 (p = 0.0002; n = 13)
and to day 533 was –10.2 ± 4.2 (p = 0.0313; n = 6). For FVC, the results were as follows: at day
169, -0.1 ± 0.4 (p = 0.2064; n = 19); at day 365, -0.2 ± 0.4 (p = 0.0413; n = 15) and at day 533,
-0.2 ± 0.2 L (p = 0.0625; n = 6). For DLCO, the changes were as follows: at day 169, -0.5 ± 9.1
(p = 0.0090; n = 18); at day 365, -0.3 ± 3.1 (p = 0.3028; n = 15) and at day 533, -2.2 ± 4.0 mL/
min/mmHg (p = 0.3125; n = 6).
Matched pairs of baseline and post-treatment skin biopsies were available for 12 subjects.
Of these, 3/12 were classified as improvers based on the change in MRSS, showing a>5 point
Table 1. Baseline demographics and disease characteristics of SSc patients (n = 31).
Parameter Value#
Mean age, years (range) 50.8 (24–77)
Female, n (%) 21 (67.7)
Aged <65 years, n (%) 26 (83.9)
Race, n (%):
• White 77.4)
• Black (9.7)
• American Indian/Alaska native (3.2)
• Other 3 (9.7)
Median disease duration, months (range)
-from the first non-Raynaud disease manifestation 14.1 (1–53)a
FVC* 2.9 ± 0.8
DLCO& 14.2 ± 4.8
MRSS* 24.5 ± 7.7
Serum markers:
• APRIL† 11.4 ± 10.8
• SP-D† ± 126.7
• KL-6† 1078.0 ± 1038.4
HRCT, whole lung:
• QGG, % ± 10.6
• QLF, % ± 9.1
• QHC*, % ± 0.4
• Total QILD*, % 24.7 ± 18.0
HRCT, most severe lobe:
• QGG, % ± 13.3
• QLF, % ± 20.8
• QHC*, % 0.2 ± 0.3
• Total QILD*, % 40.9 ± 26.5
#Unless stated otherwise, values are mean ± standard deviation
*n = 30
&n = 29
†n = 27
a27 of 31 (87.1%) treated patients had disease duration 3 years; 4 of 31 (12.9%) had disease duration >3
years dcSSc, diffuse cutaneous systemic sclerosis; DLCO, diffusing capacity for carbon monoxide; FVC,
forced vital capacity; MRSS, modified Rodnan skin score; QGG, quantitative ground glass; QLF, quantitative
lung fibrosis; QHC, quantitative honeycomb; QILD, quantitative interstitial lung disease.
https://doi.org/10.1371/journal.pone.0187580.t001
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or>20% decrease from baseline to post-treatment MRSS. The remaining subjects (9/12) were
classified as non-improvers.
Overview of quantitative HRCT results
Thirty-one patients patient had baseline ILD evaluation by quantitative HRCT. The mean val-
ues for the whole lung were as follows: QLF, 6.6%; QGG, 17.8%; QHC, 0.3%; and QILD,
24.7%. At the most severe lobe, the mean values were as follows: QLF, 16.2%; QGG, 24.4%;
QHC, 0.2%; and QILD, 40.9%. For serial evaluation, 23 matched baseline and 6 month follow-
up HRCT scans were available for analysis. The HRCT lung volumes showed a significant cor-
relation with PFT-based lung volumes both at baseline (ρ -0.50) and at follow-up (range
from ρ = -0.69 to ρ = -0.32) (S4 and S5 Tables). Based on previously described quantitative
computed tomography changes in SSc-ILD [30], subjects were classified as either “not worse”
(combining patients with stable or decreased score) or “worse” (patients with increased score)
Fig 1. CONSORT flowchart for the study.
https://doi.org/10.1371/journal.pone.0187580.g001
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at the 6-month follow-up. Using this dichotomous approach, the number of “not worse” sub-
jects in the most severe baseline lobe and whole lung was as follows: QLF, 15 and 17; QILD, 9
and 10, respectively. The number of “worse” subjects was as follows: QLF, 8 and 6; QILD, 14
and 13 (Fig 2). At the most severe lobe, 65% of patients showed no progression by QLF and
39% showed no progression by QILD. Baseline QLF at most severe lobe and whole lung
showed strong correlation with visual assessment of extent of lung fibrosis and with change in
fibrosis at 6 month follow-up (S1 Fig). HRCT images at baseline and day 169 from representa-
tive subjects with reduced, stable, and increased QLF and QILD scores are shown (Fig 3).
Weak associations between visual assessment of radiologic ILD and FVC at baseline and day
169 were found (Panels E and F in S1 Fig; p = 0.14 and p = 0.29, respectively).
Serum marker changes
We measured selected putative SSc biomarkers in the serum. Levels of both KL-6 and SP-D
were elevated at baseline, but substantial patient-to-patient variability was seen. They did not
show significant change during the 6-month study period (S6 and S7 Tables). In contrast,
serum levels of adiponectin, an anti-fibrotic adipokine previously implicated in SSc [43]
showed a significant rise post-treatment (p<0.01 for all comparisons; S2 Fig). Further analysis
revealed that baseline serum levels of SP-D and KL-6 were significantly correlated with QLF
and QILD scores (S4 Table). Associations between QLF and FVC were -0.53 (p = 0.0025) at
baseline and -0.36 (p = 0.10) for changes in the whole lung. Associations between QILD and
FVC were -0.48 (p = 0.0077) at baseline and -0.56 (p = 0.0083) for changes in the whole lung.
Changes in SP-D were significantly correlated with changes in QLF scores at both the most
severe lobe and whole lung (ρ = 0.67 (p = 0.0001), ρ = 0.68 (p = 0.0001) at baseline; ρ = 0.59
(p = 0.0035), ρ = 0.47 (p = 0.029) at day 169, respectively; S5 Table).
Skin-based intrinsic gene expression subset assignment
Gene expression profiling was performed for all 45 skin biopsy samples corresponding to 19
unique patients. These included lesional baseline and follow-up biopsies for 12 patients (24
samples) and non-lesional baseline biopsies for 11 of these 12 patients (13 samples, including
technical replicates) as well a follow-up non-lesional biopsy for one of these 12 patients (1
Fig 2. Drop plots of changes in texture-based quantitative scores from baseline using HRCT. (A) QLF
and (B) QILD for the most severe lobe. (C) QLF and (D) QILD for the whole lung. Dashed lines of ±3% and
±2% are indicators of thresholds for changes in regional analysis in lobe and whole lung, respectively.
https://doi.org/10.1371/journal.pone.0187580.g002
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sample). The remaining seven samples corresponded to baseline non-lesional skin biopsies
from a different set of seven patients.
First, each skin biopsy was assigned to an intrinsic gene expression subset. For this purpose,
we identified 3,207 probes (2,532 unique genes) at false discovery rate (FDR)<1.1% using the
intrinsic gene expression algorithm that finds genes with the most similar expression between
samples from the same patient but with the largest differences between samples from different
patients [35,44,45]. Using these genes for hierarchical sample clustering, three previously
described intrinsic subsets (fibroproliferative, inflammatory and normal-like) [35,44–46] were
observed (Fig 4A). We used g:Profiler [47] to identify functional terms significantly enriched
in gene signatures associated with intrinsic subsets (p0.05, corrected for multiple testing via
default g:Profiler method). Genes with increased expression in samples from fibroproliferative
subset (Fig 4A, red bar) were enriched in cell cycle-related terms such as mitotic cell cycle, chro-
mosome organization, cell division and microtubule cytoskeleton. Genes associated with the
inflammatory subset (Fig 4A, purple bar) showed enrichment in immune system process, defense
response and inflammatory response. Genes that were upregulated in normal-like samples (Fig
4A, green bar) were involved in lipid metabolic process, fatty acid metabolic process and lipid bio-
synthetic process. The absence in this cohort of limited intrinsic subset was not surprising, since
only subjects with dcSSc were included in this study. S8 Table contains lists of annotated probes
associated with each intrinsic subset.
Fig 3. Representative pairs of baseline and follow-up HRCT images. (A) Better case: pulmonary fibrosis
(PF) improved and ground glass opacity (GGO) worsened by the visual assessment in whole lung; (B)
annotated HRCT of (A) with a CAD system: QLF and QILD in whole lung decreased, by 2.9% (3.9% to 1.0%)
and 0.2% (19.9% to 19.7%), respectively. (C) Stable case; (D) annotated CAD of (C): QLF in the worst lobe
(lower left) increased by 2% (64% to 66%). In whole lung, QLF and QILD increased, by 2.3% (39.5% to
41.8%) and 1.8% (72.4% to 74.2%), respectively. (E) Worse case: PF worsened and GGO improved; (F)
annotated CAD of (E): QLF increased by 6.0% (28% to 34%) in the most severe lobe (lower right) and 1.8%
(9.8% to 11.6%) in whole lung. QILD in whole lung was stable (41.3% to 40.5%).
https://doi.org/10.1371/journal.pone.0187580.g003
Novel CT biomarkers and genomic subsetting of SSc-ILD
PLOS ONE | https://doi.org/10.1371/journal.pone.0187580 November 9, 2017 9 / 20
Intrinsic subset assignment and clinical response
Next, we compared the intrinsic gene expression subsets between subjects classified as clinical
improvers and non-improvers (S9 Table). Overall, 7/12 subjects with matched biopsies
mapped to the inflammatory, 2/12 to the fibroproliferative, and 3/12 to the normal-like subset
at baseline. Significantly, we found that all three clinical improvers were non-inflammatory,
mapping to the normal-like (2/3) or fibroproliferative (1/3) intrinsic subsets whereas 7/9 non-
improvers were found to map to the inflammatory intrinsic subset (p = 0.0455; Fisher’s exact
test) (Fig 4B). Three of five subjects (60%) mapping to the non-inflammatory (i.e. normal-like
and fibroproliferative) subsets were classified as improvers, whereas none of the seven subjects
(0%) mapping to the inflammatory subset were classified as improvers (Fig 4C).
Comparison of baseline gene expression between improvers and non-
improvers
We sought to compare baseline gene expression between improvers and non-improvers. This
analysis identified 1,062 genes that showed differential expression between the two groups
Fig 4. Intrinsic gene expression subset assignment and response status. (A) Intrinsic gene analysis. 3,207 probes (2,532 unique genes) at
FDR<1.1% were used to organize samples into three gene expression-based clusters (intrinsic subsets). Sample color legend: red–fibroproliferative,
purple–inflammatory, green–normal-like. (B) Distribution of patients according to their baseline intrinsic subsets and their response status. (C)
Comparison between inflammatory and non-inflammatory (fibroproliferative and normal-like) patients in terms of the percentage of improvers.
https://doi.org/10.1371/journal.pone.0187580.g004
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(p<0.05; unpaired t-test) (Fig 5A). Genes showing increased baseline expression in improvers
were enriched in cell cycle, intracellular signal transduction and MAPK cascade. The genes
showing elevated baseline expression in non-improvers were associated with defense response,
inflammatory response and leukocyte migration. There were 14 pathways that were differen-
tially expressed (FDR<10%) between improvers and non-improvers at baseline. Non-improv-
ers showed increased expression of inflammatory pathways, including complement, allograft
rejection and IL6/JAK/STAT3 signaling, among others (Fig 5B).
Changes in gene expression in improvers
Further analysis identified 454 genes that showed change from baseline to post-treatment skin
biopsies in improvers (p<0.05; paired t-test) (Fig 5C). These genes showed higher baseline
expression in improvers compared to non-improvers, and decreased post-treatment only in
improvers (p<0.0001 for both comparisons) whereas their expression showed no change in
non-improvers (p = 0.1576) (S3 Fig). Thirteen pathways (FDR<10%) were down-regulated
post-treatment in improvers (Fig 5D) and included both inflammatory (e.g. IFNA/IFNG
response and TNFA/NFKB signaling) and fibrotic gene sets (e.g. PI3K/AKT/MTOR signaling
and TGFB signaling). No such change in pathways was observed in non-improvers.
PFT results by clinical response
Lung functions (FVC and DLCO) remained stable in improvers during the course of the study
(p = 0.75 for both PFTs). In marked contrast, a significant decrease in DLCO was seen in non-
improvers (p = 0.0195; mean ± SEM -2.8 ± 1.0 mL/min/mmHg). Moreover, non-improvers
also displayed a trend toward a decline in FVC at follow-up (p = 0.1289; mean ± SEM
-0.3 ± 0.2 L).
Quantitative HRCT, clinical response and intrinsic subsets
Finally, we evaluated the radiologic parameters of lung fibrosis in improvers and non-improv-
ers, as defined above. This analysis showed that non-improvers had significantly higher QGG
scores at baseline, compared to improvers (p = 0.0364) (Fig 6A). QLF score in non-improvers
increased significantly during therapy (p = 0.0313), while it remained stable in improvers (Fig
6B). Non-improvers also tended to have a higher QILD at baseline compared to improvers
(p = 0.1212).
We next compared quantitative HRCT measures across intrinsic gene expression subsets
(S10 Table). Specifically, we examined the relative differences in terms of the imaging marker
of ground glass and fibrotic reticulation (measured as [QGG-QLF], large score indicating
higher degree of inflammation relative to fibrosis in lung). At baseline, subjects mapping to the
inflammatory subset had higher [QGG-QLF] scores (mean score 14.7%) compared to subjects
mapping to fibroproliferative (p = 0.0556; mean score 7.0%), or combined normal-like and
fibroproliferative intrinsic subsets (p = 0.0682; mean score 9.3%) (Fig 6C). Consistent with the
fact that most non-improvers mapped to the inflammatory gene expression subset, baseline
[QGG-QLF] scores were significantly higher in non-improvers compared to improvers
(p = 0.0091; mean ± SEM 14.9 ± 1.9% for non-improvers vs. 5.3 ± 0.6% for improvers) (Fig
6D).
Discussion
While recent studies in SSc have uncovered myriad potential therapeutic targets, disease-mod-
ifying treatment remains elusive. In light of remarkable disease heterogeneity that is the
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Fig 5. Baseline and improver gene expression and pathway enrichment analysis. (A) 1,062 genes were differentially expressed (p<0.05) between
improvers and non-improvers at baseline. Sample color legend: blue–improvers, orange–non-improvers. (B) 14 pathways showing differential expression
(FDR<10%) at baseline. (C) 454 genes displaying differential expression (p<0.05) between baseline and post-treatment in improvers. Sample color legend:
blue–baseline samples, black–post-treatment samples. (D) 13 pathways were differentially expressed (FDR<10%) in improvers.
https://doi.org/10.1371/journal.pone.0187580.g005
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hallmark of SSc, and the multitude and diversity of molecular drivers linked to pathogenesis,
effective interventions will require selective targeting of individual pathways in a “precision
medicine” approach [6,48]. Multiple tyrosine kinases associated with TGF-β and PDGF signal-
ing have been implicated in skin and lung fibrosis, and are potential targets for therapy [49].
We therefore performed an open-label clinical trial of dasatinib, a TKI that targets c-Abl, the
PDGF receptor and Src tyrosine kinases [50]. While dasatinib appeared to be well-tolerated in
this SSc cohort of patients with early-stage ILD, no significant changes in MRSS or PFTs were
observed. However, the pattern of changes on quantitative HRCT suggested a probable thera-
peutic response in some subjects, since the 65% showing stability of lung fibrosis during the
treatment period is significantly higher than in a placebo-treated historical cohort, in which
Fig 6. HRCT trends across improvers and non-improvers. (A) QGG trends. (B) QLF trends. (C) Baseline [QGG-QLF] marker vs. intrinsic subset. (D)
Baseline [QGG-QLF] marker vs. response status.
https://doi.org/10.1371/journal.pone.0187580.g006
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only 23% of subjects showed no progression [42]. Adverse events in dasatinib-treated SSc
patients were comparable to those seen in CML patients [51].
The extent of radiologic lung involvement at baseline is a strong predictor of both subse-
quent disease progression and mortality in patients with SSc [52]. In addition, radiologic
change in SSc-associated lung fibrosis has been shown to correlate with treatment efficacy
[33,42]. We had developed an innovative robust imaging approach for quantifying radiologic
parameters of ILD in SSc. An advantage of quantitative HRCT evaluation over conventional
visual assessment is its ability to provide a linear scale for determining absolute change [31,42].
In addition, it allows for accurate regional (lobar) measures of disease extent, and change over
time (Fig 3). As observed in this study, the most severely involved lung lobes have moderate-
to-severe disease, and change over time is best observed using this metric over whole lung
measures. In the present study, we found that the QLF score remained unchanged during the
course of dasatinib treatment in most patients, while the QILD scores increased in approxi-
mately two-thirds of patients, and QGG score increased at follow-up. Of note, non-improvers
had significantly higher baseline QGG scores compared to improvers. Additionally, the QLF
scores remained stable during the course of dasatinib treatment in improvers, while in non-
improvers these scores significantly worsened. This might suggest that the presence of a
ground glass radiological pattern in patients with SSc-ILD is indicative of active disease pro-
gressing to fibrosis; or that TKI therapy may control fibrotic, but not inflammatory, compo-
nent of the disease.
Serum levels of SP-D, KL-6 [53] and APRIL have all been previously shown to be elevated
in patients with SSc-ILD [54]. While we found levels of KL-6 and SP-D to be elevated in our
cohort of SSc-ILD patients, they exhibited marked variability and showed poor correlation
with MRSS or with improver status. In contrast, elevated levels of KL-6 and SP-D were sig-
nificantly associated with HRCT QLF scores. Adiponectin, an adipocyte-derived circulating
protein with potential utility as a biomarker [55], was shown to be reduced in patients with
SSc, and to have an inverse correlation with MRSS [43]. In the present study, we found that
adiponectin levels during the course of this trial showed a significant rise. Interestingly, adi-
ponectin expression is negatively regulated by tyrosine kinases [56], which might provide
an explanation for its up-regulation following treatment with dasatinib, and deserves fur-
ther investigation.
Skin biopsy-based gene expression analyses revealed fundamental differences between
patients classified as improvers and non-improvers. Each of the clinical improvers mapped to
non-inflammatory intrinsic gene expression subsets, whereas most non-improvers were
assigned to the inflammatory intrinsic subset. Improvers showed increased expression of cell
cycle genes while non-improvers were characterized by up-regulated expression of immune
and defense response genes. These observations indicate that baseline gene expression analysis
of skin biopsies, and in particular molecular intrinsic subset assignment, represents a valuable
approach for matching SSc patients to appropriate therapies. In particular, the present results
suggest that dasatinib is more likely to benefit SSc-ILD patients mapping to the non-inflamma-
tory intrinsic subsets than patients from the inflammatory subset. This is a significant and
novel finding, since prior examples of subset-specific responses in SSc have identified patients
mapping to the inflammatory subset as more likely to respond to immunomodulatory thera-
pies such as mycophenolate mofetil [35] or abatacept [36].
In addition to the baseline gene expression differences, we also identified genes and path-
ways that were differentially expressed between baseline and post-treatment biopsies in
improvers. Pathways that decreased in improvers represented both inflammatory and fibrotic
signaling and, importantly, included genes upregulated in response to TGF-β. There were no
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pathways that changed in non-improvers suggesting a targeted modulation by dasatinib of
inflammation and fibrosis in clinical improvers.
We recognize certain limitations of the present study. These include the absence of healthy
controls, and the absence of a placebo-treated comparator group. In view of these consider-
ations, gene expression differences between improvers and non-improvers cannot be attrib-
uted solely to the treatment effect, and could conceivably be explained by natural history of
disease. Similarly, the relatively small sample sizes hampered identification of robust differen-
tially expressed gene signatures, although we complemented this by performing differential
pathway analysis on a whole genome level and correcting for multiple hypothesis testing. It
should also be noted that since the primary objectives of this study were safety and pharmaco-
kinetics of the dasatinib treatment, skin biopsies were available only for a subset of patients.
This might potentially limit the extent to which findings from the present gene expression
analyses are representative of a larger patient population.
In a recent clinical trial of nilotinib, another TKI, in patients with dcSSc [57], we reported
that patients mapping to the inflammatory subset showed improvement on nilotinib. These
results seem to contrast with the current findings, where none of the patients from the inflam-
matory subset responded to dasatinib. This difference is arguably a reflection of the distinct
kinase inhibitory spectra of dasatinib and nilotinib [58]. Additionally, time points and clinical
response criteria differed between these two studies making it problematic to directly compare
the results. For example, in the nilotinib study, gene expression was analyzed at baseline, 6 and
12 months while in the dasatinib study, it was measured only at baseline and 6 months. More-
over, clinical endpoints (change in MRSS) were determined at 12 months for nilotinib and at 6
months for dasatinib [57]. Despite inconsistency in baseline subset assignment, clinical
improvers in both trials showed decreased expression of inflammatory and fibrotic pathways
post-treatment, which was not observed in non-improvers.
An important finding from this trial relates to the PK properties of dasatinib in SSc. Our PK
studies indicated that the Cmax and AUC were approximately 60% and 65% lower in patients
with SSc compared to healthy subjects receiving dasatinib [27]. Reduced exposure to dasatinib
in SSc patients may be due to concomitant use of proton pump inhibitors (PPIs). It was shown
previously that co-medication with antacids and/or PPIs can reduce dasatinib exposure due to
its pH-dependent absorption [51]. Since the solubility of dasatinib decreases as pH increases,
antacids and PPIs might reduce the absorption of dasatinib by increasing gastric pH [51]. Nine-
teen of 21 subjects in the present study who underwent PK evaluation were receiving therapy
with PPIs, which likely contributed to the substantial decrease in dasatinib exposure.
Conclusions
In this open-label trial, dasatinib appeared to be well-tolerated in subjects with early-stage SSc-
ILD. While no significant changes in MRSS or PFT were observed at day 169, the number of
subjects showing stability of radiological QLF score was higher than had been previously
observed in a historical placebo-treated SSc cohort [42]. Subjects classified clinically as non-
improvers were more likely to show evidence of disease progression on quantitative HRCT.
Moreover, patients mapping to the inflammatory gene expression subset were less likely to
show improvement during dasatinib treatment. The changes in skin gene expression seen in
the improvers correlated with the QLF. These results are unlikely to represent spontaneous
improvement, which is only infrequently reported in the absence of effective therapy [35,45].
Taken together, the present observations provide support for the utility of QLF and QGG eval-
uation of chest HRCT, and analyses of gene expression from baseline skin biopsies, as preci-
sion medicine tools for matching SSc patients with optimal therapies.
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